Showing results (11-20 of 4,233) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|June 24, 2019
Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytesChunwan Lu, John D Klement, Mohammed L Ibrahim, et al.Journal for Immunotherapy of Cancer|July 21, 2016
NLRC5, a promising new entry in tumor immunologySonia T Chelbi, Greta GuardaJournal for Immunotherapy of Cancer|April 23, 2015
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanomaHeinz Läubli, Cathrin Balmelli, Matthias Bossard, et al.Journal for Immunotherapy of Cancer|April 23, 2015
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumorsEmanuela Romano, Pedro RomeroJournal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F McdermottJournal for Immunotherapy of Cancer|July 17, 2020
Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cellsFangxiao Hu, Dehao Huang, Yuxuan Luo, et al.Journal for Immunotherapy of Cancer|May 5, 2023
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironmentPengfei Xu, Joy C Yang, Bo Chen, et al.Journal for Immunotherapy of Cancer|May 19, 2023
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanomaFlorian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, et al.Journal for Immunotherapy of Cancer|June 27, 2015
Immune monitoring technology primer: immunosequencingIlan KirschJournal for Immunotherapy of Cancer|July 22, 2015
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumabSaskia Jam Santegoets, Anita Gm Stam, Sinéad M Lougheed, et al.Pageof 424